Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors.

Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E, Sundlöv A, Trägårdh E.

J Nucl Med. 2019 Apr 18. pii: jnumed.119.226332. doi: 10.2967/jnumed.119.226332. [Epub ahead of print]

PMID:
31000584
2.

Development and Evaluation of Two Potential 5-HT7 Receptor PET Tracers: [18F]ENL09 and [18F]ENL10.

Tampio L'Estrade E, Xiong M, Shalgunov V, Edgar FG, Volk B, Baerentzen SL, Palner M, Erlandsson M, Ohlsson T, Knudsen GM, Herth MM.

ACS Chem Neurosci. 2019 Apr 22. doi: 10.1021/acschemneuro.9b00132. [Epub ahead of print]

PMID:
30973705
3.

Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging.

Stéen EJL, Jørgensen JT, Petersen IN, Nørregaard K, Lehel S, Shalgunov V, Birke A, Edem PE, L'Estrade ET, Hansen HD, Villadsen J, Erlandsson M, Ohlsson T, Yazdani A, Valliant JF, Kristensen JL, Barz M, Knudsen GM, Kjær A, Herth MM.

Bioorg Med Chem Lett. 2019 Apr 15;29(8):986-990. doi: 10.1016/j.bmcl.2019.02.014. Epub 2019 Feb 13.

4.

A genetic risk score for hypertension is associated with risk of thoracic aortic aneurysm.

Tagetti A, Bonafini S, Ohlsson T, Engström G, Almgren P, Minuz P, Smith G, Melander O, Fava C.

J Hum Hypertens. 2019 Jan 18. doi: 10.1038/s41371-018-0159-6. [Epub ahead of print]

PMID:
30659280
5.

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.

Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O.

Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9.

6.

Midregional proadrenomedullin predicts reduced blood pressure and glucose elevation over time despite enhanced progression of obesity markers.

Ohlsson T, Nilsson PM, Persson M, Melander O.

J Hypertens. 2019 Mar;37(3):590-595. doi: 10.1097/HJH.0000000000001893.

PMID:
30540625
7.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.

JAMA. 2018 Sep 18;320(11):1151-1162. doi: 10.1001/jama.2018.12917.

8.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.

Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, Palmqvist S, Stomrud E, Hansson O.

Alzheimers Res Ther. 2018 Aug 7;10(1):77. doi: 10.1186/s13195-018-0403-x.

9.

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M.

J Cereb Blood Flow Metab. 2018 Aug 3:271678X18791430. doi: 10.1177/0271678X18791430. [Epub ahead of print]

PMID:
30073880
10.

Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging.

T L'Estrade E, Hansen HD, Erlandsson M, Ohlsson TG, Knudsen GM, Herth MM.

ACS Chem Neurosci. 2018 Jun 20;9(6):1226-1229. doi: 10.1021/acschemneuro.8b00176. Epub 2018 May 15. Review.

PMID:
29763291
11.

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.

Sci Rep. 2018 Mar 16;8(1):4717. doi: 10.1038/s41598-018-23041-x.

12.

Quantitative analysis of phantom studies of 111In and 68Ga imaging of neuroendocrine tumours.

Jönsson L, Stenvall A, Mattsson E, Larsson E, Sundlöv A, Ohlsson T, Hindorf C.

EJNMMI Phys. 2018 Feb 20;5(1):5. doi: 10.1186/s40658-018-0204-0.

13.

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Blennow K, Jögi J, Hansson O.

Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.

14.

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.

Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S; Swedish BioFINDER study, Jögi J, Ohlsson T, Smith R, Hansson O.

Brain. 2017 Sep 1;140(9):2286-2294. doi: 10.1093/brain/awx171.

PMID:
29050382
15.

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.

Neurology. 2017 Aug 22;89(8):845-853. doi: 10.1212/WNL.0000000000004264. Epub 2017 Jul 28.

16.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

17.

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks.

Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M.

Front Neurosci. 2017 Mar 31;11:167. doi: 10.3389/fnins.2017.00167. eCollection 2017.

18.

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model.

Elgström E, Ohlsson TG, Eriksson SE.

Tumour Biol. 2017 Apr;39(4):1010428317697550. doi: 10.1177/1010428317697550.

PMID:
28381167
19.

Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension.

Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, Grarup N, Sim X, Barnes DR, Witkowska K, Staley JR, Tragante V, Tukiainen T, Yaghootkar H, Masca N, Freitag DF, Ferreira T, Giannakopoulou O, Tinker A, Harakalova M, Mihailov E, Liu C, Kraja AT, Fallgaard Nielsen S, Rasheed A, Samuel M, Zhao W, Bonnycastle LL, Jackson AU, Narisu N, Swift AJ, Southam L, Marten J, Huyghe JR, Stančáková A, Fava C, Ohlsson T, Matchan A, Stirrups KE, Bork-Jensen J, Gjesing AP, Kontto J, Perola M, Shaw-Hawkins S, Havulinna AS, Zhang H, Donnelly LA, Groves CJ, Rayner NW, Neville MJ, Robertson NR, Yiorkas AM, Herzig KH, Kajantie E, Zhang W, Willems SM, Lannfelt L, Malerba G, Soranzo N, Trabetti E, Verweij N, Evangelou E, Moayyeri A, Vergnaud AC, Nelson CP, Poveda A, Varga TV, Caslake M, de Craen AJ, Trompet S, Luan J, Scott RA, Harris SE, Liewald DC, Marioni R, Menni C, Farmaki AE, Hallmans G, Renström F, Huffman JE, Hassinen M, Burgess S, Vasan RS, Felix JF; CHARGE-Heart Failure Consortium, Uria-Nickelsen M, Malarstig A, Reily DF, Hoek M, Vogt T, Lin H, Lieb W; EchoGen Consortium, Traylor M, Markus HF; METASTROKE Consortium, Highland HM, Justice AE, Marouli E; GIANT Consortium, Lindström J, Uusitupa M, Komulainen P, Lakka TA, Rauramaa R, Polasek O, Rudan I, Rolandsson O, Franks PW, Dedoussis G, Spector TD; EPIC-InterAct Consortium, Jousilahti P, Männistö S, Deary IJ, Starr JM, Langenberg C, Wareham NJ, Brown MJ, Dominiczak AF, Connell JM, Jukema JW, Sattar N, Ford I, Packard CJ, Esko T, Mägi R, Metspalu A, de Boer RA, van der Meer P, van der Harst P; Lifelines Cohort Study, Gambaro G, Ingelsson E, Lind L, de Bakker PI, Numans ME, Brandslund I, Christensen C, Petersen ER, Korpi-Hyövälti E, Oksa H, Chambers JC, Kooner JS, Blakemore AI, Franks S, Jarvelin MR, Husemoen LL, Linneberg A, Skaaby T, Thuesen B, Karpe F, Tuomilehto J, Doney AS, Morris AD, Palmer CN, Holmen OL, Hveem K, Willer CJ, Tuomi T, Groop L, Käräjämäki A, Palotie A, Ripatti S, Salomaa V, Alam DS, Shafi Majumder AA, Di Angelantonio E, Chowdhury R, McCarthy MI, Poulter N, Stanton AV, Sever P, Amouyel P, Arveiler D, Blankenberg S, Ferrières J, Kee F, Kuulasmaa K, Müller-Nurasyid M, Veronesi G, Virtamo J, Deloukas P; Wellcome Trust Case Control Consortium, Elliott P; Understanding Society Scientific Group, Zeggini E, Kathiresan S, Melander O, Kuusisto J, Laakso M, Padmanabhan S, Porteous D, Hayward C, Scotland G, Collins FS, Mohlke KL, Hansen T, Pedersen O, Boehnke M, Stringham HM; EPIC-CVD Consortium, Frossard P, Newton-Cheh C; CHARGE+ Exome Chip Blood Pressure Consortium, Tobin MD, Nordestgaard BG; T2D-GENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD Exome+ Consortium, Caulfield MJ, Mahajan A, Morris AP, Tomaszewski M, Samani NJ, Saleheen D, Asselbergs FW, Lindgren CM, Danesh J, Wain LV, Butterworth AS, Howson JM, Munroe PB.

Nat Genet. 2016 Oct;48(10):1151-1161. doi: 10.1038/ng.3654. Epub 2016 Sep 12.

20.

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O.

Brain. 2016 Sep;139(Pt 9):2372-9. doi: 10.1093/brain/aww163. Epub 2016 Jun 29.

21.

A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.

Ohlsson T, Lindgren A, Engström G, Jern C, Melander O.

J Hypertens. 2016 Mar;34(3):445-51; discussion 451. doi: 10.1097/HJH.0000000000000821.

PMID:
26820475
22.

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.

Elgström E, Eriksson SE, Ljungberg O, Bendahl PO, Ohlsson TG, Nilsson R, Tennvall J.

EJNMMI Res. 2015 Dec;5(1):47. doi: 10.1186/s13550-015-0126-y. Epub 2015 Sep 15.

23.

Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model.

Elgström E, Eriksson SE, Ohlsson TG, Nilsson R, Tennvall J.

EJNMMI Res. 2015 Feb 12;5:3. doi: 10.1186/s13550-014-0079-6. eCollection 2015.

24.

(18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.

World J Urol. 2015 Nov;33(11):1749-52. doi: 10.1007/s00345-015-1547-y. Epub 2015 Apr 1.

PMID:
25824540
25.

Renormalization group running of neutrino parameters.

Ohlsson T, Zhou S.

Nat Commun. 2014 Oct 17;5:5153. doi: 10.1038/ncomms6153.

PMID:
25322932
26.

Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J.

Cancer Biother Radiopharm. 2014 Aug;29(6):238-46. doi: 10.1089/cbr.2014.1625. Epub 2014 Jun 27.

PMID:
24971673
27.

Cardiovascular consequences of a polygenetic component of blood pressure in an urban-based longitudinal study: the Malmö diet and cancer.

Fava C, Ohlsson T, Sjögren M, Tagetti A, Almgren P, Engström G, Nilsson P, Hedblad B, Minuz P, Melander O.

J Hypertens. 2014 Jul;32(7):1424-8; discussion 1428. doi: 10.1097/HJH.0000000000000209.

PMID:
24879493
28.

Change in cell death markers during (177)Lu-mAb radioimmunotherapy-induced rejection of syngeneic rat colon carcinoma.

Elgström E, Ljungberg O, Eriksson SE, Orbom A, Strand SE, Ohlsson TG, Nilsson R, Tennvall J.

Cancer Biother Radiopharm. 2014 May;29(4):143-52. doi: 10.1089/cbr.2013.1576. Epub 2014 Apr 2.

PMID:
24693940
29.

Comment on "Is dark matter with long-range interactions a solution to all small-scale problems of Λ cold dark matter cosmology?".

Ahlgren B, Ohlsson T, Zhou S.

Phys Rev Lett. 2013 Nov 8;111(19):199001. Epub 2013 Nov 6. No abstract available.

PMID:
24266494
30.

¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.

World J Urol. 2014 Aug;32(4):965-70. doi: 10.1007/s00345-013-1189-x. Epub 2013 Oct 20.

PMID:
24141889
31.

The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.

Örbom A, Eriksson SE, Elgström E, Ohlsson T, Nilsson R, Tennvall J, Strand SE.

J Nucl Med. 2013 Aug;54(8):1404-10. doi: 10.2967/jnumed.112.117028. Epub 2013 Jun 26.

32.

Status of non-standard neutrino interactions.

Ohlsson T.

Rep Prog Phys. 2013 Apr;76(4):044201. doi: 10.1088/0034-4885/76/4/044201. Epub 2013 Mar 12.

PMID:
23481442
33.

International Linear Collider: Another collider is not the way forward.

Ohlsson T.

Nature. 2013 Feb 7;494(7435):35. doi: 10.1038/494035d. No abstract available.

PMID:
23389533
34.

Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody.

Elgström E, Eriksson SE, Ohlsson TG, Tennvall J, Nilsson R.

Exp Hematol Oncol. 2012 Nov 13;1(1):34. doi: 10.1186/2162-3619-1-34.

35.

A niobium water target for routine production of [¹⁸F]Fluoride with a MC 17 cyclotron.

Siikanen J, Ohlsson T, Medema J, Van-Essen J, Sandell A.

Appl Radiat Isot. 2013 Feb;72:133-6. doi: 10.1016/j.apradiso.2012.10.011. Epub 2012 Oct 23.

PMID:
23208244
36.

Preprint servers: follow arXiv's lead.

Ohlsson T.

Nature. 2012 Sep 20;489(7416):367. doi: 10.1038/489367d. No abstract available.

PMID:
22996543
37.

Particle physics: Don't let furore over neutrinos blur results.

Ohlsson T.

Nature. 2012 May 16;485(7398):309. doi: 10.1038/485309a. No abstract available.

PMID:
22596143
38.

Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.

BJU Int. 2012 Nov;110(10):1501-6. doi: 10.1111/j.1464-410X.2012.11123.x. Epub 2012 Apr 13.

39.

Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.

Cancer Biother Radiopharm. 2012 Apr;27(3):175-82. doi: 10.1089/cbr.2011.1132. Epub 2012 Mar 14.

PMID:
22417248
40.

Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.

Cancer Biother Radiopharm. 2012 Mar;27(2):134-40. doi: 10.1089/cbr.2011.1080. Epub 2012 Jan 9.

PMID:
22229635
41.

Effect of charge on microvascular permeability in early experimental sepsis in the rat.

Bansch P, Nelson A, Ohlsson T, Bentzer P.

Microvasc Res. 2011 Nov;82(3):339-45. doi: 10.1016/j.mvr.2011.08.008. Epub 2011 Aug 28.

PMID:
21906604
42.

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1084-92. doi: 10.1002/cncr.24796.

43.

High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1043-52. doi: 10.1002/cncr.24791.

44.

Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer.

Bjurberg M, Kjellén E, Ohlsson T, Bendahl PO, Brun E.

Int J Gynecol Cancer. 2009 Dec;19(9):1600-5. doi: 10.1111/IGC.0b013e3181c00359.

PMID:
19955945
45.

Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro.

Bjurberg M, Henriksson E, Brun E, Ekblad L, Ohlsson T, Brun A, Kjellén E.

Cancer Biother Radiopharm. 2009 Jun;24(3):327-32. doi: 10.1089/cbr.2008.0556.

PMID:
19538055
46.

Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.

Henriksson E, Kjellén E, Baldetorp B, Bendahl PO, Borg A, Brun E, Mertens F, Ohlsson T, Rennstam K, Wennerberg J, Wahlberg P.

J Exp Clin Cancer Res. 2009 Feb 13;28:17. doi: 10.1186/1756-9966-28-17.

47.

Childhood obesity: from nutrition to behaviour.

Flodmark CE, Ohlsson T.

Proc Nutr Soc. 2008 Nov;67(4):356-62. doi: 10.1017/S0029665108008653. Epub 2008 Aug 20. Review.

PMID:
18715520
48.

Human cerebral blood volume (CBV) measured by dynamic susceptibility contrast MRI and 99mTc-RBC SPECT.

Engvall C, Ryding E, Wirestam R, Holtås S, Ljunggren K, Ohlsson T, Reinstrup P.

J Neurosurg Anesthesiol. 2008 Jan;20(1):41-4.

PMID:
18157024
49.

Regional cerebral metabolic rate (positron emission tomography) during inhalation of nitrous oxide 50% in humans.

Reinstrup P, Ryding E, Ohlsson T, Sandell A, Erlandsson K, Ljunggren K, Salford LG, Strand S, Uski T.

Br J Anaesth. 2008 Jan;100(1):66-71. Epub 2007 Nov 23.

50.

Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5572s-5576s.

Supplemental Content

Loading ...
Support Center